3D culture models have many benefits compared to 2D models, including increased physiological relevance and better prediction of in vivo responses to drug treatments. But most existing cell-based assays are designed for 2D cultures and may not produce the same results in 3D cultures. Thus, it is important to understand how 3D structures might impact assay performance and to ensure the assay is optimized for 3D models.
Join this webinar as 3D culture experts from Corning and Promega answer questions about common methods to form 3D structures, and factors to consider when evaluating cell-based assays for use with 3D structures. Learn about the novel viability and cytotoxicity assays that do not lyse cells and allow for additional multiplexing with nucleic acid purification or other markers of cell function.
Terry Riss, PhD
Senior Product Manager, Cell Health
Austin Mogen, PhD
Field Application Scientist
Corning Life Sciences
We love to talk science.
Sign up to receive monthly invitations to our webinars.